Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CASP1 | P29466 | 3/20 | 0.75 |
| ▸ | CASP7 | P55210 | 3/20 | 0.75 |
| ▸ | HBB | P68871 | 3/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | PRNP | P04156 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8891198 | 0.92 | USP2 (0.81) | USP2TP53CYP3A4CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL8899590 | 0.91 | KMT2A (0.82) | USP2TP53CYP3A4CASP1CASP7 | |
| SCHEMBL21028180 | 0.91 | USP2 (0.80) | USP2TP53CYP3A4CASP1CASP7 | |
| SCHEMBL24916533 | 0.91 | USP2 (0.77) | USP2TP53CYP3A4CASP1CASP7 | |
| SCHEMBL13340072 | 0.88 | USP2 (0.76) | USP2TP53CYP3A4CASP1CASP7 | |
| SCHEMBL6199957 | 0.87 | USP2 (0.58) | USP2TP53CYP3A4CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL6201590 | 0.86 | KMT2A (0.59) | USP2TP53CYP3A4CASP1CASP7 | |
| Quinacrine SCHEMBL1817364 | 0.86 | USP2 (1.00) | USP2TP53CYP3A4CASP1CASP7 | |
| Quinacrine SCHEMBL17704776 | 0.86 | USP2 (1.00) | USP2TP53CYP3A4CASP1CASP7 | |
| SCHEMBL6523301 | 0.86 | ADORA2A (0.61) | USP2TP53CYP3A4CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010139982-A1 | INDOLE DERIVATIVES FOR THE STIMULATION OF STEM CELL PROLIFERATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | USP2 3496/4885TP53 3713/4885CYP3A4 4074/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | USP2 3496/4885TP53 3713/4885CYP3A4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.